Reviva Pharmaceuticals Holdings annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Reviva Pharmaceuticals Holdings Stock-Based Compensation Growth & History (RVPH)
Reviva Pharmaceuticals Holdings's stock-based compensation was $2.2M for fiscal 2025.
View full Reviva Pharmaceuticals Holdings company overviewReviva Pharmaceuticals Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.2M | $597,518 | +36.65% |
| 2024 | 2024-12-31 | $1.6M | −$1.8M | −52.24% |
| 2023 | 2023-12-31 | $3.4M | $3.2M | +1831.34% |
| 2022 | 2022-12-31 | $176,735 | $70,022 | +65.62% |
| 2021 | 2021-12-31 | $106,713 | $106,713 | — |
| 2020 · Dec 31 | 2020-12-31 | $0 | $0 | — |
| 2019 · Dec 31 | 2019-12-31 | $0 | — | — |
Reviva Pharmaceuticals Holdings quarterly stock-based compensation
Q1.21
Q2.21
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $214,565 | −$180,712 | −45.72% |
| Q1 2026 | 2026-03-31 | $584,439 | −$334,680 | −36.41% |
| Q4 2025 | 2025-12-31 | $455,084 | −$99,132 | −17.89% |
| Q3 2025 | 2025-09-30 | $458,379 | $110,322 | +31.70% |
| Q2 2025 | 2025-06-30 | $395,277 | $36,284 | +10.11% |
| Q1 2025 | 2025-03-31 | $919,119 | $550,044 | +149.03% |
| Q4 2024 | 2024-12-31 | $554,216 | $163,618 | +41.89% |
| Q3 2024 | 2024-09-30 | $348,057 | −$2,353 | −0.67% |
| Q2 2024 | 2024-06-30 | $358,993 | −$2.3M | −86.30% |
| Q1 2024 | 2024-03-31 | $369,075 | $317,548 | +616.27% |
| Q4 2023 | 2023-12-31 | $390,598 | $334,012 | +590.27% |
| Q3 2023 | 2023-09-30 | $350,410 | $309,823 | +763.36% |
| Q2 2023 | 2023-06-30 | $2.6M | $2.6M | +6472.42% |
| Q1 2023 | 2023-03-31 | $51,527 | $11,841 | +29.84% |
| Q4 2022 | 2022-12-31 | $56,586 | −$5,448 | −8.78% |
| Q3 2022 | 2022-09-30 | $40,587 | $12,997 | +47.11% |
| Q2 2022 | 2022-06-30 | $39,876 | $22,787 | +133.34% |
| Q1 2022 | 2022-03-31 | $39,686 | $39,686 | — |
| Q4 2021 | 2021-12-31 | $62,034 | — | — |
| Q3 2021 · Sep 30 | 2021-09-30 | $27,590 | $27,590 | — |
| Q2 2021 · Jun 30 | 2021-06-30 | $17,089 | $17,089 | — |
| Q1 2021 · Mar 31 | 2021-03-31 | $0 | — | — |
| Q2 2021 · Sep 30 | 2020-09-30 | $0 | — | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $0 | — | — |
Reviva Pharmaceuticals Holdings stock-based compensation trends
Over the last five fiscal years, Reviva Pharmaceuticals Holdings's stock-based compensation increased from $0 to $2.2M, a change of $2.2M. The latest reported quarter, Q2 2026, shows $214,565.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Reviva Pharmaceuticals Holdings source filings ↗